Immunotherapy combo aims to stall advanced bladder cancer
NCT ID NCT04568304
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced bladder cancer that has not been treated before. Participants have a type of bladder cancer that has spread or cannot be removed by surgery and shows a protein called PD-L1. The trial compares toripalimab plus chemo against a placebo plus chemo to see if the combination delays cancer growth and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab (an immunotherapy drug) plus standard chemotherapy (gemcitabine and cisplatin or carboplatin)
- What this could lead to
- If successful, this combination could become a new first-line standard of care for people with advanced bladder cancer that expresses PD-L1, potentially extending the time before the cancer worsens.
- What could go wrong
- This is a phase 3 trial, but results are not yet known. Immunotherapies can cause immune-related side effects, and not all patients respond. The benefit over chemotherapy alone may be modest or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, China
-
Peking University First Hospital
Beijing, China
-
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study tests Nerve-Saving support for bladder cancer patients
- Could less chemo mean better quality of life for bladder cancer patients?
- New bladder cancer cocktail aims to outdo chemo
- Bladder cancer treatment patterns under the microscope
- Real-World data shows avelumab helps control advanced bladder cancer after chemo
- New hope for bladder cancer: experimental drug joins standard combo